Cross-linked Hyaluronic Acid Sub-micron Particles: in Vitro and in Vivo Biodistribution Study in Cancer Xenograft Model

Overview

Journal J Mater Sci Mater Med

Publisher Springer

Specialty Biomedical Engineering

Date 2013 Mar 9

PMID 23471500

Citations 19

Authors

F Rosso

V Quagliariello

C Tortora

A Di Lazzaro

A Barbarisi

R V Iaffaioli

Affiliations

Soon will be listed here.

Abstract

This paper focused on the biodistribution of the cross-linked hyaluronic acid (HA-NPs) sub-micron particles in tumor-bearing mice. Solvent-non solvent method followed glutaraldehyde cross-linking utilized for the fabrication of HA-NPs. Size measurement and morphological analysis were performed by dynamic light scattering and electron microscopy, respectively and the size found to be in the range of 200-400 nm. In vitro viability in LNCaP cell line was assessed by water soluble tetrazolium assay after 24 h of exposure to sub-micron particles and no toxicity was found to higher concentration of 3 mg/mL. Internalization of particles in prostate cancer cell LNCaP were studied by confocal microscopy with FITC labeled submicron particles and involvement of hyaluronan receptor mediated uptake/endocytosis was confirmed by competitive assay. Biodistribution studies were performed in xenograft prostate cancer mice model with fluorophore labeled particles and monitored in tumoral parenchyma with strong fluorescence, meanwhile very less signal in liver, kidney and spleen while no fluorescence found in lung after 24 h of systemic administration; that shown ability of this HA based system to recognize cancer tissue. These result fetched that hyaluronic acid based system is selective for tumoral site and can be utilized to deliver bioactives in specific (targeting) and controlled (temporal) manner to cancerous tissue.

Citing Articles

Scientometric Research on Trend Analysis of Nano-Based Sustained Drug Release Systems for Wound Healing.

Tang K, Cai Z, Lv Y, Liu R, Chen Q, Gu J Pharmaceutics. 2023; 15(4).

PMID: 37111653 PMC: 10145462. DOI: 10.3390/pharmaceutics15041168.

Integration of Chemoinformatics and Multi-Omics Analysis Defines ECT2 as a Potential Target for Cancer Drug Therapy.

Soltan M, Eldeen M, Sajer B, Abdelhameed R, Al-Salmi F, Fayad E Biology (Basel). 2023; 12(4).

PMID: 37106813 PMC: 10135641. DOI: 10.3390/biology12040613.

Quantification of Xanthone and Anthocyanin in Mangosteen Peel by UPLC-MS/MS and Preparation of Nanoemulsions for Studying Their Inhibition Effects on Liver Cancer Cells.

Li R, Inbaraj B, Chen B Int J Mol Sci. 2023; 24(4).

PMID: 36835343 PMC: 9965517. DOI: 10.3390/ijms24043934.

Meta-Analysis of Cardiovascular Risk Factors in Offspring of Preeclampsia Pregnancies.

Wang W, Lin R, Yang L, Wang Y, Mao B, Xu X Diagnostics (Basel). 2023; 13(4).

PMID: 36832300 PMC: 9955836. DOI: 10.3390/diagnostics13040812.

Evaluation of Immune Modulation by β-1,3; 1,6 D-Glucan Derived from in Healthy Adult Volunteers, A Randomized Controlled Trial.

Chen S, Nan F, Liu M, Yang M, Chang Y, Chen S Foods. 2023; 12(3).

PMID: 36766186 PMC: 9914031. DOI: 10.3390/foods12030659.

References

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

Zahalka M, Okon E, Gosslar U, Holzmann B, Naor D . Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent. J Immunol. 1995; 154(10):5345-55. View

Mayer B, Jauch K, Gunthert U, Figdor C, Schildberg F, Funke I . De-novo expression of CD44 and survival in gastric cancer. Lancet. 1993; 342(8878):1019-22. DOI: 10.1016/0140-6736(93)92879-x. View

de Belder A, Wik K . Preparation and properties of fluorescein-labelled hyaluronate. Carbohydr Res. 1975; 44(2):251-7. DOI: 10.1016/s0008-6215(00)84168-3. View

Torchilin V . Multifunctional nanocarriers. Adv Drug Deliv Rev. 2006; 58(14):1532-55. DOI: 10.1016/j.addr.2006.09.009. View

Reis C, Neufeld R, Ribeiro A, Veiga F . Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2007; 2(1):8-21. DOI: 10.1016/j.nano.2005.12.003. View

Matsumura Y, Maeda H . A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46(12 Pt 1):6387-92. View

Reagan-Shaw S, Nihal M, Ahmad N . Dose translation from animal to human studies revisited. FASEB J. 2007; 22(3):659-61. DOI: 10.1096/fj.07-9574LSF. View

Liu D, Pearlman E, Diaconu E, Guo K, Mori H, Haqqi T . Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc Natl Acad Sci U S A. 1996; 93(15):7832-7. PMC: 38834. DOI: 10.1073/pnas.93.15.7832. View

10.

Byrne J, Betancourt T, Brannon-Peppas L . Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008; 60(15):1615-26. DOI: 10.1016/j.addr.2008.08.005. View

11.

Sahoo S, Labhasetwar V . Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm. 2005; 2(5):373-83. DOI: 10.1021/mp050032z. View

12.

Choi K, Jeon E, Yoon H, Lee B, Na J, Min K . Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials. 2012; 33(26):6186-93. PMC: 3617484. DOI: 10.1016/j.biomaterials.2012.05.029. View

13.

Dong Y, Feng S . Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials. 2004; 25(14):2843-9. DOI: 10.1016/j.biomaterials.2003.09.055. View

14.

Platt V, Szoka Jr F . Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm. 2008; 5(4):474-86. PMC: 2772999. DOI: 10.1021/mp800024g. View

15.

Ossipov D . Nanostructured hyaluronic acid-based materials for active delivery to cancer. Expert Opin Drug Deliv. 2010; 7(6):681-703. DOI: 10.1517/17425241003730399. View

16.

Kainz C, Kohlberger P, Sliutz G, Tempfer C, Heinzl H, Reinthaller A . Splice variants of CD44 in human cervical cancer stage IB to IIB. Gynecol Oncol. 1995; 57(3):383-7. DOI: 10.1006/gyno.1995.1159. View

17.

Stauder R, Eisterer W, Thaler J, Gunthert U . CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood. 1995; 85(10):2885-99. View

18.

Uhl-Steidl M, Muller-Holzner E, Zeimet A, Adolf G, Daxenbichler G, Marth C . Prognostic value of CD44 splice variant expression in ovarian cancer. Oncology. 1995; 52(5):400-6. DOI: 10.1159/000227497. View

19.

Harris E, Kyosseva S, Weigel J, Weigel P . Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE). J Biol Chem. 2006; 282(5):2785-97. DOI: 10.1074/jbc.M607787200. View

20.

Benitez A, Yates T, Lopez L, Cerwinka W, Bakkar A, Lokeshwar V . Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res. 2011; 71(12):4085-95. PMC: 3117105. DOI: 10.1158/0008-5472.CAN-10-4610. View